BRPI0907008A2 - Métodos otimizados para liberação de dsrna alvejando o gene pcsk9 - Google Patents
Métodos otimizados para liberação de dsrna alvejando o gene pcsk9Info
- Publication number
- BRPI0907008A2 BRPI0907008A2 BRPI0907008-7A BRPI0907008A BRPI0907008A2 BR PI0907008 A2 BRPI0907008 A2 BR PI0907008A2 BR PI0907008 A BRPI0907008 A BR PI0907008A BR PI0907008 A2 BRPI0907008 A2 BR PI0907008A2
- Authority
- BR
- Brazil
- Prior art keywords
- targeting
- pcsk9 gene
- optimized methods
- dsrna
- dsrna release
- Prior art date
Links
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2496808P | 2008-01-31 | 2008-01-31 | |
| US3908308P | 2008-03-24 | 2008-03-24 | |
| US7654808P | 2008-06-27 | 2008-06-27 | |
| US18876508P | 2008-08-11 | 2008-08-11 | |
| PCT/US2009/032743 WO2009134487A2 (en) | 2008-01-31 | 2009-01-30 | Optimized methods for delivery of dsrna targeting the pcsk9 gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907008A2 true BRPI0907008A2 (pt) | 2015-07-07 |
Family
ID=41255636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907008-7A BRPI0907008A2 (pt) | 2008-01-31 | 2009-01-30 | Métodos otimizados para liberação de dsrna alvejando o gene pcsk9 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100010066A1 (pt) |
| EP (1) | EP2245039A4 (pt) |
| JP (1) | JP2011511004A (pt) |
| AU (1) | AU2009241591A1 (pt) |
| BR (1) | BRPI0907008A2 (pt) |
| CA (1) | CA2713379A1 (pt) |
| MX (1) | MX2010008394A (pt) |
| WO (1) | WO2009134487A2 (pt) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2423060T3 (es) | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| CN101484588B (zh) | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2247729B1 (en) | 2008-02-11 | 2019-05-01 | Phio Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
| AU2009307677C1 (en) | 2008-10-20 | 2022-09-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| AU2010223967B2 (en) * | 2009-03-12 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| AU2010260148A1 (en) | 2009-06-15 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
| US9187746B2 (en) | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| WO2011088309A1 (en) | 2010-01-14 | 2011-07-21 | Regulus Therapeutics Inc. | Microrna compositions and methods |
| BR112012024049A2 (pt) | 2010-03-24 | 2017-03-01 | Rxi Pharmaceuticals Corp | interferência de rna em indicações dérmicas e fibróticas |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| CA2812046A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| CA2816321A1 (en) * | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| MX360349B (es) | 2011-03-29 | 2018-10-30 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6). |
| WO2012174224A2 (en) * | 2011-06-17 | 2012-12-20 | Calando Pharmaceuticals, Inc. | Methods for administering nucleic acid-based therapeutics |
| US9228188B2 (en) * | 2011-06-21 | 2016-01-05 | Alnylam Pharmaceuticals, Inc. | Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression |
| EP3444348A1 (en) | 2011-06-21 | 2019-02-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| IL303831A (en) | 2011-11-18 | 2023-08-01 | Alnylam Pharmaceuticals Inc | Adapted RNAI factors |
| MY167390A (en) | 2011-11-18 | 2018-08-16 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| ES3065854T3 (en) | 2011-12-07 | 2026-05-08 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| EP3358013B1 (en) * | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| RU2015101113A (ru) | 2012-06-15 | 2016-08-10 | Дженентек, Инк. | Антитела против pcsk9, составы, дозы и способы применения |
| KR102096014B1 (ko) | 2012-12-05 | 2020-04-03 | 알닐람 파마슈티칼스 인코포레이티드 | PCSK9 iRNA 조성물 및 그 사용 방법 |
| ME03043B (me) | 2013-03-14 | 2018-10-20 | Alnylam Pharmaceuticals Inc | Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu |
| CA2921162A1 (en) | 2013-05-01 | 2014-11-06 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| TW201515650A (zh) | 2013-05-06 | 2015-05-01 | 艾爾妮蘭製藥公司 | 遞送經脂質調配之核酸分子之劑量及方法 |
| KR102463973B1 (ko) * | 2013-05-22 | 2022-11-07 | 알닐람 파마슈티칼스 인코포레이티드 | ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법 |
| AU2014300981B2 (en) | 2013-06-27 | 2017-08-10 | Ricc A/S | Antisense oligomers and conjugates targeting PCSK9 |
| SG11201602631XA (en) | 2013-10-04 | 2016-05-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the alas1 gene |
| CA2932753A1 (en) | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
| US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
| WO2015168172A1 (en) | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| US10280423B2 (en) | 2014-05-01 | 2019-05-07 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor B expression |
| AU2015252841B2 (en) | 2014-05-01 | 2020-03-19 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
| JP6665111B2 (ja) | 2014-05-01 | 2020-03-13 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｐｋｋ発現を調節するための組成物及び方法 |
| WO2015168605A1 (en) | 2014-05-01 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
| MX382230B (es) | 2014-05-01 | 2025-03-13 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| KR102506169B1 (ko) | 2014-09-05 | 2023-03-08 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| US10307491B2 (en) | 2015-01-30 | 2019-06-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
| CA2979712C (en) | 2015-03-25 | 2024-01-23 | The Regents Of The University Of Michigan | Nanoparticle compositions for delivery of biomacromolecules |
| KR20250005546A (ko) | 2015-04-13 | 2025-01-09 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
| PE20180800A1 (es) | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) |
| JP6896703B2 (ja) | 2015-07-31 | 2021-06-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法 |
| MX2018002158A (es) | 2015-08-25 | 2018-07-06 | Alnylam Pharmaceuticals Inc | MíTODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9). |
| WO2017048620A1 (en) * | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| HK1255699A1 (zh) | 2015-09-24 | 2019-08-23 | Ionis Pharmaceuticals, Inc. | Kras表达的调节剂 |
| CN109563509B (zh) | 2015-10-19 | 2022-08-09 | 菲奥医药公司 | 靶向长非编码rna的减小尺寸的自递送核酸化合物 |
| SI4119569T1 (sl) | 2015-11-06 | 2024-10-30 | Ionis Pharmaceuticals, Inc. | Konjugirane protismiselne spojine za uporabo v terapiji |
| EP3370708A4 (en) | 2015-11-06 | 2019-06-26 | Ionis Pharmaceuticals, Inc. | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION |
| SG11201804729RA (en) | 2015-12-07 | 2018-07-30 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| US10246709B2 (en) | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| WO2017223085A2 (en) * | 2016-06-20 | 2017-12-28 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| ES2935658T3 (es) | 2016-07-15 | 2023-03-09 | Ionis Pharmaceuticals Inc | Compuestos y métodos para la modulación de SMN2 |
| JP6989521B2 (ja) | 2016-09-02 | 2022-01-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 標的化リガンド |
| KR20190065341A (ko) | 2016-10-06 | 2019-06-11 | 아이오니스 파마수티컬즈, 인코포레이티드 | 올리고머 화합물들의 접합 방법 |
| TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| RS63836B1 (sr) | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
| JP7167059B2 (ja) | 2017-04-19 | 2022-11-08 | フィオ ファーマシューティカルズ コーポレーション | 核酸化合物の局所送達 |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| KR20200089656A (ko) | 2017-09-19 | 2020-07-27 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법 |
| CN118236391A (zh) | 2017-12-01 | 2024-06-25 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| US20200392510A1 (en) | 2018-01-15 | 2020-12-17 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
| CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| JP7438135B2 (ja) | 2018-05-09 | 2024-02-26 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｆｘｉの発現を低下させるための化合物及び方法 |
| CN108627510A (zh) * | 2018-06-06 | 2018-10-09 | 临安卡尔生物技术有限公司 | 高密度脂蛋白胆固醇检测试剂盒 |
| EP3823725A4 (en) | 2018-07-17 | 2023-05-10 | Aronora, Inc. | METHODS FOR SAFELY REDUCING THROMBOPOIETIN |
| EP3833397A4 (en) | 2018-08-08 | 2023-06-14 | Arcturus Therapeutics, Inc. | COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS |
| EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE |
| TWI869213B (zh) | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE |
| US20220273691A1 (en) | 2018-12-21 | 2022-09-01 | Ionis Pharmaceuticals, Inc. | Modulators of hsd17b13 expression |
| CN112423794A (zh) | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN113811613B (zh) | 2019-05-22 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7663951B2 (ja) | 2019-05-22 | 2025-04-17 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| WO2020238766A1 (zh) | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7757277B2 (ja) | 2019-10-14 | 2025-10-21 | アストラゼネカ・アクチエボラーグ | Ｐｎｐｌａ３発現のモジュレーター |
| CA3160657A1 (en) | 2019-11-08 | 2021-05-14 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy |
| WO2021138537A1 (en) | 2019-12-31 | 2021-07-08 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
| PH12022552258A1 (en) | 2020-02-28 | 2023-11-20 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating smn2 |
| GB2627644B (en) | 2020-03-04 | 2024-11-20 | Verve Therapeutics Inc | Method for the preparation of GalNAc-lipid nanoparticle |
| CA3167849A1 (en) | 2020-03-16 | 2021-09-23 | Daniel Mitchell | Antagonist of pcsk9 |
| CA3176196A1 (en) | 2020-04-21 | 2021-10-28 | Flagship Pioneering, Inc. | Bifunctional molecules and methods of using thereof |
| JP7820374B2 (ja) | 2020-11-18 | 2026-02-25 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | アンジオテンシノーゲン発現を調節するための化合物及び方法 |
| AU2022231003A1 (en) | 2021-03-04 | 2023-09-14 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| WO2022266486A2 (en) * | 2021-06-17 | 2022-12-22 | Sirnaomics, Inc. | Products and compositions |
| TW202328445A (zh) | 2021-08-03 | 2023-07-16 | 美商艾拉倫製藥股份有限公司 | 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法 |
| EP4380576A4 (en) | 2021-08-03 | 2026-04-29 | Verve Therapeutics Inc | RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS |
| WO2023015265A2 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides |
| WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
| CA3233755A1 (en) | 2021-10-01 | 2023-04-06 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
| CN121285630A (zh) | 2023-04-20 | 2026-01-06 | 阿达尔克斯制药有限公司 | Mapt调节组合物及其使用方法 |
| KR20260021635A (ko) | 2023-05-12 | 2026-02-13 | 아다르엑스 파마슈티컬스, 인크. | Nmda 리간드 접합 화합물 및 이의 용도 |
| IL324720A (en) | 2023-05-26 | 2026-01-01 | Adarx Pharmaceuticals Inc | SOD1 modulators and methods of using them |
| EP4722195A1 (en) * | 2023-05-31 | 2026-04-08 | National University Corporation Hokkaido University | Ph-sensitive cationic lipid and lipid nanoparticles |
| CN121712891A (zh) | 2023-06-20 | 2026-03-20 | 阿达尔克斯制药有限公司 | Lrrk2调节组合物及其使用方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054299A (en) * | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US6271359B1 (en) * | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US20030229037A1 (en) * | 2000-02-07 | 2003-12-11 | Ulrich Massing | Novel cationic amphiphiles |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| KR100872437B1 (ko) * | 2000-12-01 | 2008-12-05 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| US20080249040A1 (en) * | 2001-05-18 | 2008-10-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA) |
| US20070173473A1 (en) * | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| US7923547B2 (en) * | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| SG190613A1 (en) * | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| WO2005120152A2 (en) * | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| ATE536418T1 (de) * | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
| US20060134189A1 (en) * | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
| WO2007086883A2 (en) * | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7915230B2 (en) * | 2005-05-17 | 2011-03-29 | Molecular Transfer, Inc. | Reagents for transfection of eukaryotic cells |
| WO2007051303A1 (en) * | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
| WO2007056861A1 (en) * | 2005-11-18 | 2007-05-24 | Protiva Biotherapeutics, Inc. | Sirna silencing of influenza virus gene expression |
| CN101484588B (zh) * | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| WO2008042973A2 (en) * | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| JP5697988B2 (ja) * | 2007-12-27 | 2015-04-08 | プロチバ バイオセラピューティクス インコーポレイティッド | 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法 |
| JP5749494B2 (ja) * | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | 核酸の送達のための改善された組成物および方法 |
| NZ588583A (en) * | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| CA2746514C (en) * | 2008-12-10 | 2018-11-27 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
| TR201811076T4 (tr) * | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| AU2010260148A1 (en) * | 2009-06-15 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
-
2009
- 2009-01-30 BR BRPI0907008-7A patent/BRPI0907008A2/pt not_active IP Right Cessation
- 2009-01-30 CA CA2713379A patent/CA2713379A1/en not_active Abandoned
- 2009-01-30 MX MX2010008394A patent/MX2010008394A/es active IP Right Grant
- 2009-01-30 JP JP2010545236A patent/JP2011511004A/ja active Pending
- 2009-01-30 EP EP09739290A patent/EP2245039A4/en not_active Withdrawn
- 2009-01-30 WO PCT/US2009/032743 patent/WO2009134487A2/en not_active Ceased
- 2009-01-30 AU AU2009241591A patent/AU2009241591A1/en not_active Abandoned
- 2009-06-04 US US12/478,452 patent/US20100010066A1/en not_active Abandoned
-
2011
- 2011-09-26 US US13/245,730 patent/US20120016009A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2245039A2 (en) | 2010-11-03 |
| CA2713379A1 (en) | 2009-11-05 |
| WO2009134487A2 (en) | 2009-11-05 |
| MX2010008394A (es) | 2010-11-12 |
| JP2011511004A (ja) | 2011-04-07 |
| AU2009241591A1 (en) | 2009-11-05 |
| WO2009134487A3 (en) | 2010-02-04 |
| EP2245039A4 (en) | 2012-06-06 |
| US20120016009A1 (en) | 2012-01-19 |
| US20100010066A1 (en) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012003257A2 (pt) | organismos homozigotos para modificação direcionada | |
| IL216886A0 (en) | Lipid formulated dsrna targeting the pcsk9 gene | |
| BRPI0917204A2 (pt) | variantes estruturais de anticorpos para melhores características terapêuticas | |
| BR112012004807A2 (pt) | vacina para pcsk9 | |
| EP2245039A4 (en) | OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN | |
| BRPI0820153A2 (pt) | Aperfeiçoamento de ação direta para rifles | |
| PT2853545T (pt) | Anticorpo específico para ige | |
| BRPI1014262A2 (pt) | anticorpos específicos para caderina-17 | |
| BRPI0924258A2 (pt) | métodos para otimizar e para determinar desempenho de reservatório | |
| LT2313364T (lt) | Simetrinio dimetilarginino nustatymo būdai | |
| DE502009000614D1 (de) | Anhängekupplung | |
| BRPI0822916A2 (pt) | Combustível sólido | |
| BRPI0910286A2 (pt) | métodos para transformação de levedura | |
| BRPI0911625A2 (pt) | Métodos | |
| BRPI0917294A2 (pt) | sistema híbrido para grelhar - elemento elétrico para grelhar | |
| DK2329319T3 (da) | Forbedret nanoimprint fremgangsmåde | |
| BRPI0912251A2 (pt) | aço de elevadas características para peças maciças. | |
| PT3957754T (pt) | Método para detetar o vírus chikungunya | |
| BRPI1011786A2 (pt) | métodos para codificação artimética. | |
| DE112009001792A5 (de) | Antriebsstrang | |
| ES1067523Y (es) | Tarima para alcorques | |
| ES1070148Y (es) | Macolla para barrotes mejorada | |
| ES1067339Y (es) | Foco para vehiculos | |
| ES1065835Y (es) | Caperuza para cetreria | |
| FI20086007L (fi) | Muodostusosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |